Delivery of extracellular vesicles loaded with immune checkpoint inhibitors for immunotherapeutic management of glioma

被引:1
|
作者
Lin, Shang-Wen [1 ]
Yu, Cheng-Ping [1 ]
Tsai, Jui-Chen [1 ]
Shyong, Yan-Jye [1 ]
机构
[1] Natl Cheng Kung Univ, Coll Med, Sch Pharm, 1,Univ Rd, Tainan 701, Taiwan
关键词
Extracellular vesicles; Immune checkpoint inhibitors; Calcium phosphate particles; Glioma; Immunotherapy; Brain delivery; DRUG-DELIVERY; GLIOBLASTOMA ERADICATION; RELEASE; EXOSOMES; BLOCKADE; BRAIN; CELL;
D O I
10.1016/j.mtbio.2024.101244
中图分类号
R318 [生物医学工程];
学科分类号
0831 ;
摘要
Glioma is a common primary malignant brain tumor with low survival rate. Immunotherapy with immune checkpoints inhibitors (ICI) can be a choice for glioma management, and extracellular vesicles (EVs) are recognized as a potential drug delivery system for various disease management due to their enhanced barrier permeation ability and immunomodulatory effect. The aim of this study is to develop ICI-loaded EVs (ICI/EV) that have sufficient efficacy in managing glioma. Calcium phosphate particles (CaP) were used to stimulate the secretion of EVs from murine macrophage cells. CaP conditioning of cells showed an enhanced amount of EVs secretion and macrophage polarization toward a proinflammatory phenotype. The CaP-induced EVs were shown to polarize macrophages into proinflammatory phenotype in vitro, as correlated with the conditioning method. ICI/EVs were successfully prepared with high loading efficiency using the sonication method. The EVs can be distributed throughout the entire brain upon intranasal administration and facilitate ICIs distribution into glioma lesion. Combinatory treatment with ICI/EVs showed benefit in glioma-bearing mice by reducing their tumor volume and prolonging their survival. Cytotoxic T cell infiltration, polarization of tumor-associated macrophage, and lower tumor proliferation were observed in ICI/EVs-treated mice. The developed ICI/EVs showed promise in immunotherapeutic management of glioma.
引用
收藏
页数:13
相关论文
共 50 条
  • [1] Extracellular Vesicles, Circulating Tumor Cells, and Immune Checkpoint Inhibitors: Hints and Promises
    Bandini, Sara
    Ulivi, Paola
    Rossi, Tania
    CELLS, 2024, 13 (04)
  • [2] Immune Checkpoint Inhibitors in Human Glioma Microenvironment
    Ghouzlani, Amina
    Kandoussi, Sarah
    Tall, Mariam
    Reddy, Konala Priyanka
    Rafii, Soumaya
    Badou, Abdallah
    FRONTIERS IN IMMUNOLOGY, 2021, 12
  • [3] Phenotypic and Proteomic Analysis Identifies Hallmarks of Blood Circulating Extracellular Vesicles in NSCLC Responders to Immune Checkpoint Inhibitors
    Brocco, Davide
    Lanuti, Paola
    Pieragostino, Damiana
    Cufaro, Maria Concetta
    Simeone, Pasquale
    Bologna, Giuseppina
    Di Marino, Pietro
    De Tursi, Michele
    Grassadonia, Antonino
    Irtelli, Luciana
    De Lellis, Laura
    Veschi, Serena
    Florio, Rosalba
    Federici, Luca
    Marchisio, Marco
    Miscia, Sebastiano
    Cama, Alessandro
    Tinari, Nicola
    Del Boccio, Piero
    CANCERS, 2021, 13 (04) : 1 - 16
  • [4] Immune Checkpoint Inhibition in GBM Primed with Radiation by Engineered Extracellular Vesicles
    Tian, Tian
    Liang, Ruyu
    Erel-Akbaba, Gulsah
    Saad, Lorenzo
    Obeid, Pierre J.
    Gao, Jun
    Chiocca, E. Antonio
    Weissleder, Ralph
    Tannous, Bakhos A.
    ACS NANO, 2022, 16 (02) : 1940 - 1953
  • [5] Circulating Extracellular Vesicles as Biomarkers for Immune-Checkpoint Inhibitors in Advanced NSCLC
    Signorelli, D.
    Fortunato, O.
    Pontis, F.
    Capizzuto, V.
    Ferri, R.
    Brambilla, M.
    Ferrara, R.
    Proto, C.
    Lo Russo, G.
    Prelaj, A.
    Galli, G.
    De Toma, A.
    Viscardi, G.
    Lobefaro, R.
    Nichetti, F.
    Ganzinelli, M.
    Zilembo, N.
    Colombo, M.
    Sozzi, G.
    Garassino, M. C.
    Jachetti, E.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S405 - S405
  • [6] Glioma-derived extracellular vesicles selectively suppress immune responses
    Hellwinkel, Justin E.
    Redzic, Jasmina S.
    Harland, Tessa A.
    Gunaydin, Dicle
    Anchordoquy, Thomas J.
    Graner, Michael W.
    NEURO-ONCOLOGY, 2016, 18 (04) : 497 - 506
  • [7] Circulating CD81-expressing extracellular vesicles as biomarkers of response for immune-checkpoint inhibitors in advanced NSCLC
    Signorelli, Diego
    Ghidotti, Patrizia
    Proto, Claudia
    Brambilla, Marta
    De Toma, Alessandro
    Ferrara, Roberto
    Galli, Giulia
    Ganzinelli, Monica
    Lorusso, Giuseppe
    Prelaj, Arsela
    Occhipinti, Mario
    Viscardi, Giuseppe
    Capizzuto, Valentina
    Pontis, Francesca
    Petraroia, Ilaria
    Ferretti, Anna Maria
    Colombo, Mario Paolo
    Torri, Valter
    Sozzi, Gabriella
    Garassino, Marina Chiara
    Jachetti, Elena
    Fortunato, Orazio
    FRONTIERS IN IMMUNOLOGY, 2022, 13
  • [8] Programmed death-ligand 1-expressing extracellular vesicles are a prognostic factor in patients with oral squamous cell carcinoma treated with immune checkpoint inhibitors
    Seki, Yuki
    Yamana, Keisuke
    Yoshida, Ryoji
    Inoue, Junki
    Shinohara, Kosuke
    Oyama, Toru
    Kubo, Ryuta
    Nagata, Masashi
    Kawahara, Kenta
    Hirayama, Masatoshi
    Takahashi, Nozomu
    Nakamoto, Masafumi
    Hirosue, Akiyuki
    Kariya, Ryusho
    Okada, Seiji
    Nakayama, Hideki
    JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY MEDICINE AND PATHOLOGY, 2024, 36 (04) : 518 - 525
  • [9] Autoimmunity and management of the Immune-related adverse effects of the Immune Checkpoint inhibitors
    Senant, Marie
    Giusti, Delphine
    Weiss, Laurence
    Dragon-Durey, Marie-Agnes
    BULLETIN DU CANCER, 2016, 103 : S175 - S185
  • [10] Autophagy inhibitors enhance biomolecular delivery efficiency of extracellular vesicles
    Zhang, Yuanyuan
    Huang, Meijuan
    Jiang, Lijun
    Li, Tongjuan
    Wang, Jue
    Zhao, Lei
    Zhou, Jianfeng
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2022, 603 : 130 - 137